Search results for "Randia"

showing 10 items of 91 documents

Postprandial adaptation of intestinal lipid metabolism : role of CD36 and PPAR beta

2011

Postprandial hypertriglyceridemia is an emerging risk factor for cardiovascular diseases and is associated with metabolic syndrome, obesity and insulin resistance. The small intestine participates in the postprandial triglyceridemia since both the size and number of secreted chylomicrons modulate lipoprotein lipase activity (LPL). Chylomicron synthesis is a complex mechanism in which the lipidation of Apolipoprotein B48 (ApoB48) by the Microsomal Triglyceride Transfer Protein (MTP) and the transfer between reticulum and Golgi in which the Liver Fatty Acid Binding Protein (L -FABP) is involved are limiting steps. An intestinal fat-mediated adaptation in postprandial period has been demonstra…

[SDV.SA]Life Sciences [q-bio]/Agricultural sciences[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTriglycéridémie postprandialedigestive oral and skin physiologyPostprandial triglyceridemiaRécepteurPPAR betaPPAR béta[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyChylomicronslipids (amino acids peptides and proteins)CD36[ SDV.SA ] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyReceptor
researchProduct

Tavallisen ihmisen uskottavuus mainoksen suosittelijana ja uskottavuuden vaikutus asenteeseen mainosta ja brandia kohtaan

2012

Tutkimuksen tavoitteena oli tutkia tavallisten ihmisten käyttöä mainoksen suosittelijoina, tavallisen ihmisen uskottavuutta suosittelijana ja uskottavuuden vaikutusta asenteeseen mainosta ja brandia kohtaan. Aikaisempaa tutkimusta aiheesta löytyi melko vähän, joten teoriapohjana käytettiin source credibility –teoriaa, jota on käytetty julkisuuden henkilöitä mainosten suosittelijoina tutkittaessa. Muiden aikaisempien tutkimustulosten perusteella mallia muokattiin niin, että tavallisen ihmisen uskottavuus suosittelijana oletettiin muodostuvan luotettavuudesta, asiantuntijuudesta ja samankaltaisuudesta. Tutkimukseen valittiin kolme erilaista, ulkonäköön liittyvää mainosta, joissa suosittelijoi…

bränditsuosittelijaasenne mainosta kohtaanbrandiasenneasenteetuskottavuusmainokset
researchProduct

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

2009

Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in response to food intake play an important role. In recent years, the 'incretin-based' therapies (IBTs) have been developed to address hyperglycemia through either mimicking the action of the endogenous incretin glucagon-like polypeptide (GLP-1) (GLP-1 receptor agonists) or by inhibiting the activity of the enzyme that degrades GLP-1 (the dipeptyl peptidase-4 inhibitors).We reviewed available evidence on the glucose lowering and anti-atherogenic effects of IBT…

endocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 410265 Clinic for Endocrinology and DiabetologyIncretin610 Medicine & healthType 2 diabetesCarbohydrate metabolismIncretinsInsulin resistancecardiovascular risk diabetes DPP-4 inhibitors GLP-1 analoguesGlucagon-Like Peptide 1Risk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumans2736 Pharmacology (medical)Pharmacology (medical)Dipeptidyl peptidase-4PharmacologyClinical Trials as TopicDipeptidyl-Peptidase IV Inhibitorsbusiness.industrydigestive oral and skin physiologyGeneral MedicineAtherosclerosismedicine.diseaseGlucose3004 PharmacologyEndocrinologyPostprandialDiabetes Mellitus Type 2aterosclerosibusinesshormones hormone substitutes and hormone antagonistsHormoneExpert Opinion on Investigational Drugs
researchProduct

Lipemia postprandial y regulación génica en la obesidad mórbida

2018

La obesidad es una enfermedad multifactorial que ocasiona una alteración metabólica crónica. Los pacientes con obesidad mórbida presentan un riesgo elevado de desarrollar enfermedades cardiovasculares, así como de presentar resistencia a la insulina implicada en la patogenia del síndrome metabólico y el desarrollo de diabetes mellitus tipo 2. La incapacidad actual para prevenir o revertir el desarrollo de la obesidad nos obliga a buscar estrategias alternativas para identificar a aquellos sujetos con un mayor riesgo de desarrollar complicaciones cardiometabólicas. La heterogeneidad existente parece no poder explicarse por los factores de riesgo “clásicos” conocidos. La lipemia postprandial …

epigenéticaUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::Genética clínica:CIENCIAS MÉDICAS ::Ciencias clínicas::Genética clínica [UNESCO]lipemia postprandialobesidad
researchProduct

Sobrecarga oral con grasa insaturada y estrés oxidativo en sujetos con obesidad abdominal

2015

Introducción: la enfermedad cardiovascular (ECV) constituye la primera causa de morbimortalidad en los países desarrollados. La base patogénica de la ECV es la arteriosclerosis. La obesidad abdominal (OA) es una de las principales causas para el desarrollo de alteraciones metabólicas como insulinorresistencia (IR), DM-2, HTA, y dislipemia mixta y por tanto del riesgo de desarrollar arteriosclerosis y ECV. La OA y la IR generan estrés oxidativo, mecanismo implicado en el desarrollo de la arteriosclerosis. Los sujetos con OA e IR presenta un aumento de estrés oxidativo tanto en estado basal como postprandial. Desde varias décadas se considera la lipemia postprandial (LPP) como un factor de ri…

estrés oxidativo:CIENCIAS MÉDICAS ::Medicina interna::Endocrinología [UNESCO]lipemia postprandialgrasa insaturadaobesidad abdominalenfermedad cardiovascularUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Endocrinologíasobrecarga oral grasainsulinorresistencia
researchProduct

Influencia de la situación postprandial sobre el eje CCL11/CCR3 en sujetos con hipercolesterolemia

2020

Introducción: La enfermedad cardiovascular es la principal causa de morbilidad y mortalidad a nivel mundial y su base patogénica es la arteriosclerosis (AE). La hipercolesterolemia primaria es uno de los factores de riesgo más importantes para la AE y este proceso está asociado a cierto grado de inflamación sistémica, habiéndose descrito en la actualidad varias citoquinas quimiotácticas involucradas en el proceso arteriosclerótico. Se ha detectado la influencia de la eotaxina-1 (CCL11) y de su receptor, CCR3, en la aparición y desarrollo de la arteriosclerosis, así como la influencia de la lipemia postprandial (LPP) como factor de riesgo independiente de enfermedad cardiovascular, aunque no…

inflamaciónUNESCO::CIENCIAS MÉDICASeotaxinapostprandialhipercolesterolemiaCCR3:CIENCIAS MÉDICAS [UNESCO]CCL11
researchProduct

Mécanisme d’absorption intestinale des acides gras à longue chaîne : rôle émergent du CD36

2012

International audience; Excessive lipid intake, associated with a qualitative imbalance, favors the development of obesity and associated diseases. Among the organs involved in lipid homeostasis, the small intestine remains the most poorly known although it is responsible for the lipid bioavailability and largely contributes to the regulation of postprandial hypertriglyceridemia. The mechanism of long chain fatty acid (LCFA) intestinal absorption is not totally elucidated. The synthesis of recent literature indicates that the intestine is able to adapt its absorption capacity to the fat content of the diet. This adaptation takes place through a fat-coordinated induction of LBP and apolipopr…

lipid absorption[SDV]Life Sciences [q-bio]CD36Postprandial hypertriglyceridemiaMedicine (miscellaneous)lcsh:TP670-699intestinal adaptationHypertriglycéridémie postprandiale030204 cardiovascular system & hematologyBiochemistryIntestinal absorption03 medical and health sciences0302 clinical medicineLipid-binding proteinsChylomicronsmedicineCd36intestinesensing030304 developmental biologyIntestinal lipid absorption0303 health sciencesNutrition and DieteticsbiologyChemistryIntestinal lipid absorptionHypertriglyceridemiamedicine.diseaseMolecular biologySmall intestine3. Good healthBioavailabilitymedicine.anatomical_structurePostprandialBiochemistrybiology.proteinlipids (amino acids peptides and proteins)lcsh:Oils fats and waxesAbsorption intestinale des lipidesLong chain fatty acid[SDV.AEN]Life Sciences [q-bio]/Food and NutritionFood ScienceChylomicronOléagineux, Corps gras, Lipides
researchProduct

AT1 Receptor Gene Polymorphisms in relation to Postprandial Lipemia

2011

Background. Recent data suggest that the renin-angiotensin system may be involved in triglyceride (TG) metabolism. We explored the effect of the common A1166C and C573T polymorphisms of the angiotensin II type 1 receptor (AT1R) gene on postprandial lipemia.Methods. Eighty-two subjects measured daytime capillary TG, and postprandial lipemia was estimated as incremental area under the TG curve. The C573T and A1166C polymorphisms of the AT1R gene were determined.Results. Postprandial lipemia was significantly higher in homozygous carriers of the 1166-C allele (9.39±8.36 mM*h/L) compared to homozygous carriers of the 1166-A allele (2.02±6.20 mM*h/L) (P<0.05). Postprandial lipemia was similar…

medicine.medical_specialtyAngiotensin II receptor type 1Article SubjectTriglyceridebusiness.industrydigestive oral and skin physiologyMetabolismAngiotensin IIchemistry.chemical_compoundPostprandialEndocrinologychemistryRC666-701Internal medicineClinical StudyDiseases of the circulatory (Cardiovascular) systemMedicineAlleleCardiology and Cardiovascular MedicinebusinessReceptorGene
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Management of Dyslipidemia in the Metabolic Syndrome

2007

In order to characterize the metabolic syndrome it becomes necessary to establish a number of diagnostic criteria. Because of its impact on cardiovascular morbidity/mortality, considerable attention has been focussed on the dyslipidemia accompanying the metabolic syndrome. The aim of this review is to highlight the fundamental aspects of the pathophysiology, diagnosis, and the treatment of the metabolic syndrome dyslipidemia with recommendations to clinicians. The clinical expression of the metabolic syndrome dyslipidemia is characterized by hypertriglyceridemia and low levels of high-density lipoprotein-cholesterol (HDL-C). In addition, metabolic syndrome dyslipidemia is associated with hi…

medicine.medical_specialtyBioinformaticsClofibric Acidchemistry.chemical_compoundInsulin resistanceInternal medicineHyperlipidemiamedicineHumansPharmacology (medical)DyslipidemiasMetabolic Syndromemedicine.diagnostic_testCholesterolbusiness.industryCholesterol HDLHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseEndocrinologyPostprandialchemistrySpainPractice Guidelines as Topiclipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsMetabolic syndromeCardiology and Cardiovascular MedicineLipid profilebusinessDyslipidemiaAmerican Journal of Cardiovascular Drugs
researchProduct